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Abstract: Eleven new secoiridoid aglycones involving unusual C9-skeleton: swerimilegenins A–F (1–6); bis-C9-skeleton:  
swerimilegenin G (7); and C10-skeleton: swerimilegenins H−K (8−11), as well as six known ones, were isolated from the  
low-polarity part of the traditional Chinese herb medicine Swertia mileensis. Their structures were determined by extensive  
spectroscopic data and X-ray diffraction. Biogenetically, swerimilegenin A (1) belonged to 10-nor-secoiridoid, and swerimilegenins 
B–F (2–6) were 1-nor-secoiridoids. Erythrocentaurin (12) and gentiogenal (15) showed moderate anti-HBV activity on HepG 
2.2.15 cell line in vitro. 
Keywords: Swertia mileensis, swerimilegenins, secoiridoid aglycones, anti-HBV activity
Introduction 
Secoiridoids, are biogenetically derived from the cleavage 
of the cylcopentane ring of iridiods (generally between C-7 
and C-8), and represent a large and still expanding group of 
monoterpenoids. Secoiridoids are widely present in mainly in 
Gentianales, Dipsacales, Cornales and Oleaceae.1,2 They have 
attracted significant interest from scientists for their diverse 
bioactivities, and conferred a diverse array of actions such as 
antiviral, cardiovascular, choleretic, hypoglycemic, anti-
inflammatory and purgative activities, and chemotaxonomic 
significance.3 Secoiridoids consistently have a hemiacetal  
hydroxy group at C-1 position, which is unstable and apt to be 
glycosylated, thus most of the secoiridoids from natural  
resources are secoiridoid glycosides.4 According to the carbon 
numbers involved in the aglycone part, secoiridoids can be 
classified into three main types: I) the normal skeleton with 
ten carbons; II) skeletons with more than ten carbons in the  
aglycone part; and III) skeletons with less than ten carbons. 
Presently, quite a few cases of secoiridoids other than C10 
skeleton have been reported.5–7 Subsequently, the discovery of 
more secoiridoid aglycones with dissimilar skeletons will help 
to formulate a greater understanding of these compounds. 
Previous investigations of Swertia mileensis (‘Qing-Ye-
Dan’ in Mandarin), which is a well-known traditional Chinese 
herb, endemic to the Yunnan province and documented in 
every edition of the Chinese Pharmacopoeia from 1977–2010, 
has shown that secoiridoid glycosides, xanthones and  
triterpenoids were their active constituents.8–10 As an ongoing 
search for anti-hepatitis B virus (anti-HBV) active compounds 
from natural resources, our recent investigation on the  active 
part of S. mileensis resulted in a series of novel lactones,  
swerilactones A–O and swerilactosides A–C.11–17 From a  
biosynthetic perspective, swerilactones A and B (C18 skeleton) 
were derived from two C9 secoiridoids, and swerilactones H–
K (C29 skeleton) were condensed by two C10 and one C9  
secoiridoids. In addition, swerilactone G and swerilactosides 
A and B also contained the characteristic C9 secoiridoid moie-
ties 
in their structures. The above analysis suggests that S. mileensis
may be rich in secoiridoid aglycones, especially for the unusual
C9 skeletons. Secoiridoids without glycosylation should be 
present in the low-polarity part of S. mileensis, however this 
part was ignored in the previous investigation, for its low-
content and less-activity. Therefore, further investigation was 
focused on secoiridoid aglycones and was performed on the 
low-polarity part of S. mileensis, resulting in eleven new  
(1–11), as well as six pre-existing compounds (12–17). This 
paper will discuss their isolation, structural elucidation, and 
anti-HBV properties on HepG 2.2.15 cell line in vitro. 
 
Results and Discussion 
Compound 1 had the molecular formula of C9H12O4, which 
was determined by negative HRESIMS ([M – H]–, detected at 
m/z 183.0686, calcd for 183.0663), indicating four degrees of 
unsaturation. In the 13C NMR (DEPT) spectrum, three  
quaternary carbons, one methine and five methylenes, were 
observed. An α,β-unsaturated δ-lactone was proposed from the 
characteristic carbons at δC 163.0, 125.3, 149.5, 65.9 and 26.8, 
and HMBC correlations of H-7/C-5 and C-11, and H-6/C-4, 
which was in accordance with the UV (222 nm) and IR (1701 
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and 1631 cm−1) absorptions. Therefore, four residual carbons 
(three O-bearing methylenes and one methine) required an 
additional ring to fulfill the unsaturation. The connectivity of 
O-C(8)-C(9)-C(1)-O was constructed by the 1H-1H COSY 
experiment (H-8/H-9/H-1), of which C-9 was proposed to be 
attached with C-5 by HMBC correlations from H-1 and H-8 to 
C-5 (Figure 1). In HMBC spectrum, correlations from δH 4.43 
and 4.29 (H-3) to δC 149.5 (C-5), 163.0 (C-11) and 66.5 (C-1) 
suggested that C-3 was directly linked to C-4 and further  
cyclized with C-1 by an oxygen atom. The configuration at  
C-9 was determined as R-form based on its optical rotation 
([α]18D   – 12.4) and in comparison to the known compounds 
with the similar chiral center.18,19 Thus, the structure of  
compound 1 was determined and named as swerimilegenin A. 
Compound 2 was assigned the molecular formula of 
C9H14O3 by HREIMS which showed [M]+ at m/z 170.0944 
(calcd. 170.0943), with three degrees of unsaturation. The 
existence of hydroxy and carbonyl groups was verified by IR 
absorptions at 3430 and 1711 cm–1. Nine carbons involving 
three quaternary ones, five methylenes and one methyl were 
detected in the 13C NMR (DEPT) spectrum. The characteristic 
signals at δC 166.2 (s, C-11), 156.8 (s, C-5), 126.2 (s, C-4), 
65.5 (t, C-7) and 28.6 (t, C-6) enabled the α,β-unsaturated  
δ-lactone moiety. A propyl group was proposed at C-5 based 
on 1H-1H COSY (H-10/H-8/H-9) and HMBC experiments  
(H-9/C-4, C-6 and H-8/C-5). One remaining oxygenated 
methylene (C-3) was recognized with a hydroxmethyl group 
and assigned at C-4 according to the HMBC correlations of  
H-3/C-4 and C-5. Thus, the structure of compound 2 was  
constructed. 
Compound 3 possessed the molecular formula of C9H12O3 
(four unsaturations) deduced from the pseudo-molecular ion 
peak of [M + Na]+ (m/z 191) in ESIMS and [M + H]+ (m/z 
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Figure 1.  Selected 2D NMR correlations for compounds 1–11 
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compound 3 were similar to those of 2, except that the  
hydroxymethyl (C-3) and methylene (C-9) in 2 were changed 
to be methyl and carbonyl in 3. Two groups of adjacent  
protons at δH 1.15 (t, J = 7.2 Hz, H-10) and 2.64 (q, J = 7.2 Hz, 
H-8) in 1H NMR spectrum, together with the carbons at δC 
204.6 (s), 35.1 (t) and 7.4 (q) in 13C NMR (DEPT) spectrum 
suggested a propionyl group which was proposed at C-5 based 
on the HMBC correlations of H-8/C-5 and H-6/C-9. The  
remaining singlet methyl was assigned at C-4 by the long 
range correlations of H-3 with C-4, C-5 and C-11 in HMBC 
experiment. 
Compound 4 was obtained as a hemiacetal analogue with 
the molecular formula of C9H12O4 by a positive HRESIMS 
experiment ([M + Na]+ at m/z 207.0624 and [2M + Na]+ at m/z 
391.1245). The existence of hydroxy (3385 cm–1) and carbon-
yl (1686 cm–1) groups was specified in IR spectrum. A  
characteristic δ-lactone fragment was recognized from its 1H 
and 13C NMR data (Table 1). Besides the δ-lactone part, four 
residual carbons involving one di-oxygenated methine (C-3), 
one mono-oxygenated methine (C-8), one methylene (C-9), 
and one methyl (C-10), were proposed to occupy a cyclic  
pattern in agreement with the unsaturation degree. The proton 
signals at δH 1.17 (3H, d, J = 6.3 Hz, H-10), 4.28 (1H, m, H-8), 
2.24 (1H, dd, J = 18.8, 3.6 Hz, H-9a) and 2.12 (1H, dd, J = 
18.8, 10.8 Hz, H-9b) in 1H NMR spectrum, as well as the  
1H-1H COSY correlations of H-10/H-8/H-9 manifested the 
connectivity of CH3-CH(O-)-CH2-, which was allocated at C-5 
by HMBC cross-peaks from H-8 to C-5, and from H-9 to C-4, 
C-5 and C-6. The hemiacetal methine (C-3) was determined to 
be directly linked with C-4 and further cyclized with C-8 by 
an O-bridge based on the HMBC experiment (H-3/C-5, C-8 
and C-11; HO-3/C-4; H-8/C-3). 
In order to determine the stereochemistry of C-3 and C-8, a 
ROESY experiment was performed, however the key  
correlation of H-8 or H-10 with H-3 was not detected. This 
phenomenon is frequently encountered in secoiridoids whose 
structure contains a six-member ring fused with a δ-lactone 
fragment. The connection of C(10)-C(8)-O-C(3)-H bears a 
stable W configuration which makes a homolateral H-3 and  
H-10 departure from each other. Meanwhile, the hydroxyl 
group at C-3 was apt to form intramolecule hydrogen bond 
with O=C(11), resulted in OH-3 apart from H-8. Therefore, no 
correlation of H-3/H-10 or OH-3/H-8 was observed in the 
ROESY experiment, despite having been located at the same 
orientation. In this case, the dihedral angles of H-9a/H-8 and 
H-9b/H-8 are about 56.8° and 176.4° according to the Chem 
3D model calculation (Figure 2), which are consistent with the 
coupling constants of 3.6 Hz (JH-9a/H-8) and 10.8 Hz (JH-9b/H-8). 
In addition, compound 7, the dehydrated dimer of 4, was also 
obtained and unambiguously determined by X-ray single  
crystal diffraction. Compounds 4 and 7 had the almost  
identical NMR spectral data and similar specific rotation value 
(–2.06° for 4, about half of –6.65° for 7) indicating the same 
stereochemistry. 
Compound 5 was proposed the molecular formula of 
C10H14O4 based on positive HRESIMS, 14 mass units (CH2) 
higher than swerimilegenin D (4). Its 1H and 13C NMR  
spectroscopic data were similar to those of 4 except for an 
additional methoxy group (δH 3.48, δC 55.7). With the aid of 
HMBC analysis, the methoxy group was deduced at C-3 by 
the correlation of OMe with C-3. Similar to swerimilegenin D, 
no correlation between H-3 (or OMe) and H-8 (or H-10) was 
detected in the ROESY experiment due to the W configuration. 
The stereocenters of C-3 and C-8 in compound 5 were  
deduced to be the same as those of 4 by comparing their  
coupling constant in 1H NMR spectrum and [α]D values.  
Compound 6 was designated the molecular formula of 
C10H12O5 by positive HRESIMS ([M + Na]+, as detected at m/z 
235.0586, calcd. for 235.0582). A methoxy group was  
speculated by the ion peak at m/z 181 (M+ – OMe) in the 
EIMS spectrum. Its 1H and 13C NMR data were similar to 
those of 5, except for the additional carbonyl group (196.6, s) 
instead of methylene [δC 36.8 (t, C-9)] in 5. The C(9)=O was 
evidenced based on the HMBC correlations of H-10/C-9,  
H-8/C-9 and C-5. Similar to compounds 4 and 5, neither  
H-8/H-3 nor Me-10/H-3 was detected in its ROESY spectrum 
due to the stable W configuration. The stereochemistry of 
compound 6 was proposed to be the same as compounds 4 and 




















Figure 2.  The W configuration in the Chem 3D model of 
compound 4 
Table 1. 1H and 13C NMR data for compounds 1–5 (δ in ppm, J in Hz) 
 
NO. 
1a 2a 3a 4b 5a
δH δC δH δC δH δC δH δC δH δC
1 4.03, dd, 11.4, 2,7 
3.74, dd, 11.4, 3.5 
66.5, t – – – – – – – –
3 4.43, br. d, 16.2 
4.29, br. d, 16.2 
64.4, t 4.35, s 57.3, t 2.00, s 14.2, q 5.57, d, 5.0 87.7, d 5.25, s 94.1, d
4 – 125.3, s – 126.2, s – 127.1, s – 125.4, s – 123.6, s
5 – 149.5, s – 156.8, s – 147.5, s – 153.7, s – 153.1, s
6 2.60, m 
2.43, m 
26.8, t 2.45, t, 6.1 28.6, t 2.61, m 25.7, t 2.57, ddd, 17.8, 8.0, 
5.9 
2.35, dt, 17.8, 4.5 
29.0, t 2.55, m 
2.27, dt, 17.9, 4.6 
28.4, t
7 4.42, m 65.9, t 4.34, t, 6.1 65.5,t 4.40, t, 6.1 65.6, t 4.35, m 65.9, t 4.37, m 65.1, t
8 3.88, m 62.9, t 1.53, m 21.0, t 2.64, q, 7.2 35.1, t 4.28, m 61.6, d 4.20, m 61.3, d
9 2.34, br. s 40.3, d 2.34, t, 7.4 35.1, t – 204.6, s 2.24, dd, 18.8, 3.6
2.12, dd, 18.8, 10.8 
37.2, t 2.17, dd, 19.2, 8.7
2.14, dd, 19.2, 4.3 
36.8, t
10 – – 0.94, t, 7.4 13.9, q 1.15, t, 7.2 7.4, q 1.17, d, 6.3 21.2, q 1.29, d, 6.3 20.7, q
11 – 163.0, s – 166.2, s – 165.4, s – 163.1, s – 162.4, s
OMe/OH – – – – – – 5.38, d, 5.0 – 3.48, s 55.7, q
aMeasured in CDCl3; bMeasured in acetone-d6 
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rotation value ([α]24D   = – 4.0). 
Compound 7 was determined with the molecular formula of 
C18H22O7 from positive HRESIMS (detected at m/z 373.1258). 
Only nine carbons and 11 protons were displayed in the 13C 
and 1H NMR spectra, indicating a symmetrical skeleton. Its 1H 
and 13C NMR spectral data were almost identical with those of 
4, indicating the similar structures. The above analysis together
with its molecular formula of C18H22O7 (18 mass units less 
than two molecules of 4) suggested that compound 7 should be 
the dehydrated dimer of 4, which was finally confirmed by 
extensive 2D NMR experiment and X-ray single crystal  
diffraction (Figure 3). 
Compound 8 possessed the molecular formula of C10H12O4 
in accordance with the ion peaks of M+ at m/z 196 in EIMS 
and [M + Na]+ at m/z 219.0641 in HRESIMS. The presence of 
OH and C=O groups was evidenced by the absorption bands at 
3362 and 1699 cm–1 in IR spectrum. An obvious α,β-
unsaturated δ-lactone fragment was revealed from its 1H and 
13C NMR spectroscopic data (Table 2). In addition, one 
CH3CH=C moiety was proposed to be linked with C-5 and C-
1 from the HMBC correlations of H-8 with C-5, H-6 with C-9 
and H-1 with C-5 and C-8. The HMBC correlations of H-3 
with C-4, C-5 and C-1 revealed the linkage of C(4)-C(3)-O-
C(1). The Z-form of the double bond between C-8 and C-9 
was determined by the correlation of H-8 with H-6 in the 
ROESY spectrum.  
Compound 9 had the molecular formula of C11H14O4 as a 
result of a positive HRESIMS experiment, with an additional 
CH2 moiety compared to compound 8. Its IR, UV and NMR 
spectroscopic data were similar to 8, except for an additional 
methoxy group. In HMBC spectrum, the correlations of 
OCH3/C-1 and H-1/OCH3 indicated that the methoxy group 
was located at C-1 position. Finally, its structure was  
determined by an X-ray single crystal diffraction experiment. 
Compound 10 was proposed with a molecular formula of 
C10H14O4 by HREIMS at m/z 198.0897. The IR spectrum  
displayed the absorption bands at 3472, 1679, 1595 and 1404 
cm–1 denoting the presence of OH, C=O and C=C groups. Its 
NMR spectroscopic data was close to that of dihydroepinau-
cledal (14), indicating a similar structure. From its 1H-1H 
COSY and HMBC experiments, compound 10 was established 
the same planar structure as 14. Therefore, their 1H and 13C 
NMR spectral differences (Table 3) might be ascribed to the 
stereochemical variation. In the ROESY spectrum, the  
correlations of H-5 with H-9 and H-10, and H-1 with H-8 sug-
gested the same orientation of H-5 with H-9 and H-10, which 
display an obvious difference from the ROESY experiment of 
14, in which the correlations of H-5/H-1 and H-10, and H-9/H-
8 were observed (see Electronic Supplementary Material). 
Compound 11 possessed the molecular formula of C10H14O4 
identical with swerimilegenin J from HRESIMS. The same 
planar structures of 11 with 10 and 14 were constructed based 
on extensive 1H-1H COSY and HMBC analysis. In the ROESY
spectrum, the correlations of H-5 with H-1 and H-8, and H-9 
Table 2. 1H and 13C NMR data for compounds 6–9 (δ in ppm, J in Hz) 
 
NO. 
6a 7b 8c 9a
δH δC δH δC δH δC δH δC
1 – – – – 5.90, d, 5.0 88.0, d 5.42, s 94.7, d
3 5.46, d, 1.2 93.0, d 6.27, s 88.2, d 4.50, d, 16.0
4.23, d, 16.4 
56.5, t 4.41, m 56.7, t
4 – 135.8, s – 123.3, s – 131.3, s – 130.8, s
5 – 139.9, s – 154.8, s – 142.8, s – 142.4, s
6 2.66, m 19.6, t 2.30, ddd, 17.5, 9.6, 6.5
2.06, dt, 17.5, 4.9 
28.6, t 2.63, m
2.55, m 
22.4, t 2.56, m 22.4, t
7 4.48, m 66.4, t 4.23, m 65.7, t 4.39, m 65.7, t 4.41, m 65.6, t
8 4.64, q, 6.5 69.6, d 4.71, m 62.5, d 6.12, q, 7.3 130.7, d 6.09, q, 7.1 130.7, d
9 – 196.6, s 2.00, dd, 18.8, 10.8
1.88, dd, 18.8, 3.8 
36.6, t – 120.4, s – 120.7, s
10 1.45, d, 6.5 15.6, q 1.36, d, 6.3 20.8, q 1.89, d, 7.3 13.8, q 1.89, d, 7.1 13.8, q
11 – 162.4, s – 162.8, s – 164.2, s – 163.8, s
OMe/OH 3.59, s 57.0, q – – 5.49, d, 5.0 – 3.51, s 55.1, q
aMeasured in CDCl3; bMeasured in C5D5N; cMeasured in acetone-d6 
 
Figure 3.  X-ray crystal structures of compounds 7 and 9 
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with H-10 manifested the α-orientation of H-5, H-8 and  
hydroxymethyl (C-1), and the β-orientation of H-9 and Me-10. 
The known dihydroepinaucledal (14) was determined by 
comparing its NMR data with that of a previous report20 and 
further confirmed by a 2D NMR experiment (see Electronic 
Supplementary Material). The other known compounds were 
determined as erythrocentaurin (12),21 gentiolactone (13),22 
gentiogenal (15),23 secostrychnosin (16)24 and angelone (17)5 
by comparing their spectroscopic data to existing report data. 
In order to evaluate their anti-HBV properties, namely  
inhibiting the secretions of hepatitis B surface antigen (HBsAg) 
and hepatitis B e antigen (HBeAg), as well as HBV DNA  
replication, the isolates were assayed on HepG 2.2.15 cell line 
in vitro (Table 4). Most of the tested compounds exhibited low 
activity and cytotoxicity at the highest tested concentration, 
except for erythrocentaurin and gentiogenal. Erythrocentaurin 
could inhibit the HBsAg secretion and HBV DNA replication 
with the IC50 values of 1.39 ± 0.54 and 0.96 ± 0.45 mM,  
respectively. Gentiogenal showed activity inhibiting the  
secretion of HBsAg and HBeAg with the IC50 values of 3.92 ± 
0.82 and 2.99 ± 0.72 mM. 
Previously, most of the secoiridoids isolated from Swertia 
plants were secoiridoid glycosides and always contained a C10 
aglycone part. Interestingly, this investigation resulted in  
eleven new secoiridoid aglycones including unusual C9-
skeleton (1–6), bis-C9-skeleton (7) and C10-skeleton (8–11) 
from the low-polarity part of S. mileensis. Structurally,  
compound 1 belonged to 10-nor-secoiridoid, and compounds 
2–6 were attributed to 1-nor-secoiridoids, which further  
enriched the skeleton types of secoiridoids. It is concluded that 
diverse secoiridoid aglycones are contained in S. mileensis, 
although these compounds may be not corresponding to the 
anti-HBV activity in vitro. 
 
Experimental Section 
General Experimental Procedures. Melting points were 
measured on a SGWX-4B instrument (Shanghai Jingke, 
Shanghai, China). 1D and 2D NMR spectra were recorded on 
Bruker AV-400 NMR, DRX-500 or AVANCE III-600  
spectrometers (Bruker, Bremerhaven, Germany) corrected by 
deuterated solvent signals. MS data was collected on LCMS-
IT-TOF (Shimadzu, Kyoto, Japan) or VG Auto Spec-3000 
(VG, Manchester, UK) spectrometers. IR (KBr) spectra was 
recorded on a Bruker Tensor 27 FT-IR (Bruker Optics GmbH, 
Ettlingen, Germany). UV data was collected on a Shimadzu 
UV-2401A spectrophotometer (Shimadzu, Kyoto, Japan).  
Optical rotations were collected on a Jasco model 1020 polar-
imeter (Horiba, Tokyo, Japan). Sephadex LH-20 (20–150 m) 
was purchased from Pharmacia Fine Chemicals Co. Ltd. 
(Pharmacia, Uppsala, Sweden). Silica gel (200–300 mesh) for 
column chromatography was obtained from Qingdao Makall 
Chemical Company (Makall, Qingdao, China). CHP20P MCI 
gel (Mitsubishi Chemical Corporation, Tokyo, Japan) and 
Merck Lichrosorb RP-18 (Merck KGaA, Darmstadt, Germany) 
were applied for medium pressure liquid chromatographic 
(MPLC) preparation, which was performed on a Dr-Flash-S 
MPLC system (Lisui, Suzhou, China). Agilent Eclipse XDB-
C18 column (Agilent Technologies, Santa Clara, USA) was 
used for semi-preparation, which was conducted on a Waters 
600-2695 HPLC instrument (Waters, Milford, MA, USA), 
equipped with a photodiode array detector (Waters 2996). 
 
Plant Material. The whole plants of Swertia mileensis T. N. 
Ho et W. L. Shi were collected in Mile County, Yunnan  
Province, China, in November, 2008, and were identified by 
Prof. Li-Gong Lei. A voucher specimen (No. 2008-11-01) was 
deposited in the Laboratory of Antivirus and Natural Medicine 
Chemistry, Kunming Institute of Botany, CAS. 
 
Extraction and Isolation. The air-dried and powered whole 
plant (5.0 kg) of S. mileensis was extracted with ethanol and 
condensed to provide a residue (1.3 kg). The residue was  
partitioned between water and petroleum ether (PE, 1 L × 2), 
ethyl acetate (EtOAc, 1 L × 3) and n-butanol (1 L × 3)  
successively. The EtOAc part (170 g) was chromatographed 
on silica gel column (2 kg, 110 mm id × 500 mm) eluted with 
CHCl3-MeOH to provide fractions A−J. Fraction A (29 g) was 
separated by silica gel column chromatography (CC, 300 g, 50 
mm id × 240 mm) with an eluent of CHCl3-Me2CO system 
(0:100 → 50:50, v/v) to yield Frs. A1−A5.11 Frs. A1 and A2 
were combined based on TLC detection which displayed many 
identical spots both under UV detector and treated with H2SO4 
regent, and subjected to silica gel CC (200 g, 25 mm id  600 
mm) eluted with CHCl3/MeOH gradient (100:0, 95:5, 90:10 
and 80:20, with 2 L, respectively), to obtain three fractions 
A1A–A1C. Fraction A1B (5 g) was separated by CHP20P MCI 
gel column chromatography (100.0 g, 25 mm id  300 mm) on 
a MPLC system eluted with MeOH/H2O (from 20:80 to 80:20, 
10 L) to yield seven sub-fractions (Frs. A1B-1 to A1B-7). Fr.  
A1B-1 (300 mg) was purified with a silica gel column (50 g, 25 
mm id  150 mm) eluting with PE/acetone (from 80:20 to 
Table 3. 1H and 13C NMR data for compounds 10, 11 and dihydroepinaucledal (14) (δ in ppm, J in Hz) 
 
NO. 
10a 11a 14a 
δH δC δH δC δH δC
1 3.74, dd, 10.4, 5.8 
3.48, dd, 10.4, 8.6 
60.1, t 3.90, d, 2.7 59.2, t 3.76, dd, 10.8, 5.1 
3.45, dd, 10.8, 8.7 
60.9, t
3 7.69, d, 2.2 155.3, d 7.71, s 156.5, d 7.61, d, 1.8 155.6, d
4 – 101.6, s – 104.6, s – 102.4, s
5 2.88, dddd, 11.5, 5.8, 5.8, 2.2 28.2, d 2.74, ddd, 12.4, 12.4, 1.9 31.3, d 2.31, dddd, 11.6, 11.6, 4.0, 1.8 28.4, d
6 1.86, m 25.4, t 2.15, m
1.52, m 
27.6, t 2.02, m
1.55, m 
26.9, t
7 4.49, ddd, 11.3, 4.1, 2.4 
4.30, ddd, 11.3, 11.3, 3.9 
68.5, t 4.47, ddd, 11.3, 4.3, 1.9
4.30, ddd, 11.3, 11.3, 2.4 
68.3, t 4.40, ddd, 11.5, 4.4, 1.8 
4.23, ddd, 11.5, 11.5, 2.5 
68.0, t
8 4.76, qd, 6.5, 1.2 73.0, d 4.18, dq, 10.4, 6.3 75.2, d 4.61, qd, 6.8, 4.6 73.5, d
9 1.95, dddd, 8.6, 5.8, 5.8, 1.2 39.8, d 1.23, dddd, 12.4, 10.4, 2.7, 2.7 44.2, d 1.77, dddd, 11.6, 8.7, 5.1, 4.6 41.7, d
10 1.35, d, 6.5 19.3, q 1.44, d, 6.3 18.8, q 1.16, d, 6.8 14.1, q
11 – 166.2, s – 166.5, s – 166.4, s
aMeasured in CDCl3 
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50:50, 800 mL) to afford compounds 3 (6 mg), 6 (8 mg), 12 
(150 mg) and 15 (9 mg). Compounds 4 (5.0 mg), 5 (5.0 mg), 7 
(6.0 mg), 8 (9.0 mg) and 9 (6.0 mg) were isolated from Fr. 
A1B-2 (100 mg) by Sephadex LH-20 (50.0 g, 14 mm id  1450 
mm, MeOH, 300 mL) and repeated silica gel CC (20 g, 14 mm 
id  250 mm, PE/acetone = 80:20, 500 mL). Fr. A1B-3 (400 mg) 
was separated by RP-18 column (50 g, 25 mm id  130 mm) 
eluted with MeOH/H2O (40:60, 1000 mL) on MPLC system 
and further purified by repeated silica gel CC to give  
compounds 1 (3 mg), 2 (3 mg) and 13 (6 mg). Compounds 17 
(7 mg) and 16 (3 mg) were obtained from Fr. A1B-4 (60 mg) by 
repeated silica gel CC (20 g, 14 mm id  250 mm) eluted with 
PE/acetone (70:30, 300 mL) and CHCl3/acetone (85:15, 300 
mL) systems. Fr. A1B-5 (50 mg) was loaded on a HPLC  
apparatus using an Eclipse XDB-C18 column (94 mm id  250 
mm, 5 μm) and eluted with MeOH-H2O (25:75, flow rate = 3 
mL/min) providing compounds 10 (4 mg), 11 (6 mg) and 14 (8 
mg). The purity of all the isolates was proposed to be higher 
than 95% based on TLC (only one spot under UV radiation 
and iodine atmosphere) and NMR (smooth baseline without 
impurity peaks) methods. 
 
Swerimilegenin A (1): white amorphous powder; [α]18D   – 
12.4 (c 0.06, MeOH); UV (MeOH) λmax (log ε) 222 (3.54) nm; 
IR (KBr) νmax 3418, 2926, 1701, 1631, 1413, 1385, 1048 cm–1; 
for 1H and 13C NMR data, see Table 1; HRESIMS m/z 
183.0686 [M – H]– (calcd. for C9H11O4, 183.0663). 
 
Swerimilegenin B (2): white amorphous powder; UV 
(MeOH) λmax (log ε) 223 (3.82) nm; IR (KBr) νmax 3430, 2963, 
1711, 1469, 1404, 1314, 1170, 1142, 1074, 1008 cm–1; 1H and 
13C NMR data, see Table 1; HREIMS m/z 170.0944 M+ (calcd. 
for C9H14O3, 170.0943). 
 
Swerimilegenin C (3): white amorphous powder; UV 
(MeOH) λmax (log ε) 229 (3.83) nm; IR (KBr) νmax 2939, 1720, 
1403, 1309, 1173, 1130, 1072, 1130, 795 cm–1; 1H and 13C 
NMR data, see Table 1; ESIMS m/z 191 [M + Na]+; 
HRESIMS m/z 169.0866 [M + H]+ (calcd. for C9H13O3, 
169.0864). 
 
Swerimilegenin D (4): white amorphous powder; [α]25D   – 
2.0 (c 0.2, MeOH); UV (MeOH) λmax (log ε) 209 (3.89) nm; IR 
(KBr) νmax 3385, 2976, 1686, 1405, 1279, 1169, 1086, 1056, 
1023, 986 cm–1; 1H and 13C NMR data, see Table 1; EIMS m/z 
184 M+ (17), 183 (100), 167 (53), 140 (76), 125 (55), 94 (50); 
HRESIMS m/z 207.0624 [M + Na]+ (calcd. for C9H12O4Na, 
207.0633). 
 
Swerimilegenin E (5): white amorphous powder; [α]22D   – 
6.1 (c 0.2, MeOH); UV (MeOH) λmax (log ε) 207 (3.87) nm; IR 
(KBr) νmax 2908, 1712, 1410, 1279, 1150, 983, 966 cm–1; 1H 
and 13C NMR data, see Table 1; HRESIMS m/z 221.0763 [M 
+ Na]+ (calcd. for C10H14O4Na, 221.0784). 
 
Swerimilegenin F (6): colorless gum; [α]24D   – 4.0 (c 0.2, 
MeOH); UV (MeOH) λmax (log ε) 227 (3.87) nm; IR (KBr) νmax 2937, 1727, 1700, 1415, 1214, 1083, 1060, 975, 851 cm–1; 
1H and 13C NMR data, see Table 2; EIMS m/z 181 (35), 168 
(100), 151 (25), 140 (20), 110 (17), 82 (55); ESIMS m/z 235 
[M + Na]+; HRESIMS m/z 235.0586 [M + Na]+ (calcd. for 
C10H12O5Na, 235.0582). 
 
Swerimilegenin G (7): colorless cubic crystals; mp 228–
230 °C; [α]26D   – 6.6 (c 0.3, MeOH/CHCl3); UV (MeOH) λmax 
(log ε) 210 (4.22) nm; IR (KBr) νmax 2976, 2936, 2908, 1721, 
1707, 1473, 1414, 1323, 1281, 1156, 1060, 962, 809, 661, 561 
cm–1; 1H and 13C NMR data, see Table 2; ESIMS m/z 373 [M 
+ Na]+; HRESIMS m/z 373.1258 [M + Na]+ (calcd. for 
C18H22O7Na, 373.1263). 
 
Swerimilegenin H (8): colorless gum; [α]25D   – 3.9 (c 0.4, 
MeOH); UV (MeOH) λmax (log ε) 273 (3.78), 237 (3.82) nm; 
IR (KBr) νmax 3362, 2954, 1699, 1637, 1419, 1286, 1064, 1030, 
912, 773, 747 cm–1; 1H and 13C NMR data, see Table 2; EIMS 
m/z 196 M+ (10), 178 (90), 167 (20), 149 (24), 121 (30), 105 
Table 4. Anti-HBV activities of the isolates from S. mileensis (mM) 
 
Compounds 
MTT HBsAg HBeAg HBV DNA
CC50 IC50 SIa IC50 SI IC50 SI
1 > 1.55 > 1.55 –b > 1.55 − > 0.39 −
2 > 1.62 > 1.62 − > 1.62 − > 0.40 −
3 > 3.86 > 3.86 − > 3.86 – > 0.98 –
4 > 2.67 > 2.67 – > 2.67 – > 0.67 –
5 > 2.83 > 2.83 – > 2.83 – > 0.71 –
6 > 6.52 > 6.52 – > 6.52 – > 1.63 –
7 > 1.40 > 1.40 – > 1.40 – > 0.35 –
8 > 2.70 > 2.70 – > 2.70 – > 0.68 –
9 > 0.64 > 0.64 – > 0.64 – > 0.16 –
10 > 2.47 > 2.47 – > 2.47 – > 0.62 –
11 > 2.07 > 2.07 – > 2.07 – > 0.52 –
12 1.97 ± 0.38d 1.39 ± 0.54 1.4 2.84 ± 0.79 <1 0.96 ± 0.45 2.0
13 > 0.69 > 0.69 – > 0.69 – > 0.17 –
14 > 0.55 > 0.55 – > 0.55 – > 0.14 –
15 3.97 ± 0.78 3.92 ± 0.82 1.0 2.99 ± 0.72 1.3 > 1.24 –
16 > 1.13 > 1.13 − > 1.13 − > 0.28 −
17 > 0.44 > 0.44 – > 0.44 – > 0.11 –
tenofovirc > 1865.36 > 1865.36 – > 1865.36 3.12 ± 0.78 > 597.9
aSI (selective index: CC50/IC50); bIC50 and CC50 values were not reached at the (highest) tested concentrations. 
cTenofovir was used as the positive control; dResults were expressed as the mean (mM) ± standard deviations (SD) from three  
independent experiments. 
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(26), 91 (100), 79 (25), 77 (45); ESIMS m/z 219 [M + Na]+; 
HRESIMS m/z 219.0641 [M + Na]+ (calcd. for C10H12O4Na, 
219.0633). 
 
Swerimilegenin I (9): colorless needles; mp 144–145 °C; 
[α]16D   – 2.4 (c 0.1, MeOH); UV (MeOH) λmax (log ε) 273 (4.21), 
212 (3.66), 191 (3.90) nm; IR (KBr) νmax 2915, 1700, 1637, 
1426, 1304, 1246, 1160, 1124, 1054, 1041 cm–1; 1H and 13C 
NMR data, see Table 2; ESIMS m/z 233 [M + Na]+; 
HRESIMS m/z 211.0964 [M + H]+ (calcd. for C11H15O4, 
211.0970). 
 
Swerimilegenin J (10): colorless gum; [α]13D   – 90.6 (c 0.1, 
MeOH); UV (MeOH) λmax (log ε) 250 (3.98) nm; IR (KBr) νmax 3472, 2893, 1679, 1595, 1404, 1272, 1209, 1100, 1041, 
962, 760 cm–1; 1H and 13C NMR data, see Table 3; EIMS m/z 
199 [M + H]+ (40), 198 M+ (50), 168 (70), 127 (95), 123 (45), 
97 (50), 57 (100); HREIMS m/z 198.0897 M+ (calcd. for 
C10H14O4, 198.0892). 
 
Swerimilegenin K (11): colorless gum; [α]19D   + 2.2 (c 0.2, 
MeOH); UV (MeOH) λmax (log ε) 249 (3.60) nm; IR (KBr) νmax 3431, 2921, 1695, 1614, 1409, 1277, 1110, 1053 cm–1; 1H 
and 13C NMR data, see Table 3; HRESIMS m/z 233.0567 [M 
+ Cl]– (calcd. for C10H14O4Cl, 233.0586). 
 
Crystallographic Data of Compounds 7 and 9: Swerimi-
legenin G (7): C18H22O7, MW = 350.14; monoclinic, space 
group p21; a = 9.5350(17) Å, b = 8.4098(15) Å, c = 21.881(4) 
Å, β = 101.266(2), V = 1720.8(5) Å3, Z = 7, d = 1.315 g/cm3, 
crystal dimensions 0.28 × 0.19 × 0.08 mm3 were used for 
measurement on a Rigaku D/MAX-3B X-ray diffractometer 
with a graphite monochromater, Mo Kα radiation. The total 
number of reflections measured was 10830, of which 4045, 
were observed, I > 2σ(I). Final indices: R1= 0.0523, wR2 = 
0.1341. 
Swerimilegenin I (9): C11H14O4, MW = 210.22; monoclinic, 
space group p21; a = 4.287(2) Å, b = 9.320(5) Å, c = 
27.001(14) Å, β = 100.268(9), V = 1061.6(9) Å3, Z = 2, d = 
1.315 g/cm3, crystal dimensions 0.20 × 0.13 × 0.06 mm3 were 
used for measurement on a Rigaku D/MAX-3B X-ray diffrac-
tometer with a graphite monochromater, Mo Kα radiation. The 
total number of reflections measured was 5809, of which 1253, 
were observed, I > 2σ(I). Final indices: R1= 0.1011, wR2 = 
0.4433. 
 
Anti-HBV Assay. The anti-HBV procedure was performed 
in accordance with our previous report.15 Tenofovir (Lot No. 
200904009, purity > 97.6%) was used as the positive control, 
which was purchased from Jiangxi Chenyang Pharmaceutical 
Co. Ltd.. 
 
Electronic Supplementary Material 
Supplementary material is available in the online version of 
this article at http://dx.doi.org/10.1007/s13659-013-0059-y 
and is accessible for authorized users. 
 
Acknowledgments 
This work was funded by the National Natural Science 
Foundation of China and Yunnan Province (U0832603), the 
National Science Foundation of China for Distinguished 
Young Scholars (81025023), the West Light Foundation of the 
Chinese Academy of Sciences, the International Foundation 
for Science (No. F/5202-1), and the Youth Innovation  
Promotion Association, CAS. 
 
Open Access This article is distributed under the terms of the  
Creative Commons Attribution License which permits any use,  
distribution, and reproduction in any medium, provided the original 
author(s) and source are credited. 
 
References 
[1] Boros, C. A.; Stermitz, R. S. J. Nat. Prod. 1990, 53, 1055–1147. 
[2] El-Naggar, L. J.; Beal, J. L. J. Nat. Prod. 1980, 43, 649–707. 
[3] Dinda, B.; Debnath, S.; Harigaya, Y. Chem. Pharm. Bull. 2007, 55, 
159–222. 
[4] Jensen, S. R.; Schripsema, J. Gentianaceae-Systematic and Natural 
History: Gentianaceae-Systematics and Natural History. Cam-
bridge: Cambridge University, 2002; pp 573–630. 
[5] Mulholland, D. A.; Langlois, A.; Randrianarivelojosia, M.; Derat, 
E.; Nuzillard, J. M. Phytochem. Anal. 2006, 17, 87–90. 
[6] He, K.; Ma, Y. B.; Cao, T. W.; Wang, H. L.; Jiang, F. Q.; Geng, C. 
A.; Zhang, X. M.; Chen, J. J. Planta Med. 2012, 78, 814–820. 
[7] Wang, H. L.; Geng, C. A.; Ma, Y. B.; Zhang, X. M.; Chen, J. J. 
Fitoterapia 2013, 89, 183−187. 
[8] Kikuzaki, H.; Kawasaki, Y.; Kitamura, S.; Nakatani, N. Planta 
Med. 1996, 62, 35–38. 
[9] Li, X. S.; Jiang, Z. Y.; Wang, F. S.; Ma, Y. B.; Zhang, X. M.; 
Chen, J. J. Chin. J. Chin. Mater. Med. 2008, 33, 2790–2793. 
[10] Zhou, Y.; Di, Y. T.; Gesang, S.; Peng, S. L.; Ding, L. S. Helv. 
Chim. Acta 2006, 89, 94–102. 
[11] Geng, C. A.; Jiang, Z. Y.; Ma, Y. B.; Luo, J.; Zhang, X. M.; 
Wang, H. L.; Shen, Y.; Zuo, A. X.; Zhou, J.; Chen J. J. Org. Lett. 
2009, 11, 4120–4123. 
[12] Geng, C. A.; Zhang, X. M.; Shen, Y.; Zuo, A. X.; Liu, J. F.; Ma, 
Y. B.; Luo, J.; Zhou, J.; Jiang, Z. Y.; Chen, J. J. Org. Lett. 2009, 
11, 4838–4841. 
[13] Geng, C. A.; Zhang, X. M.; Ma, Y. B.; Jiang, Z. Y.; Luo, J.; 
Zhou, J.; Wang, H. L.; Chen, J. J. Tetrahedron Lett. 2010, 51, 
2483–2485. 
[14] Geng, C. A.; Zhang, X. M.; Ma, Y. B.; Jiang, Z. Y.; Liu, J. F.; 
Zhou, J.; Chen, J. J. J. Asian Nat. Prod. Res. 2010, 12, 542–548. 
[15] Geng, C. A.; Wang, L. J.; Zhang, X. M.; Ma, Y. B.; Huang, X. 
Y.; Luo, J.; Guo, R. H.; Zhou, J.; Shen, Y.; Zuo, A. X.; Jiang, Z. 
Y.; Chen, J. J. Chem. Eur. J. 2011, 17, 3893–3903. 
[16] Geng, C. A.; Zhang, X. M.; Ma, Y. B.; Luo, J.; Chen, J. J. J. Nat. 
Prod. 2011, 74, 1822–1825. 
[17] Geng, C. A.; Wang, L. J.; Guo, R. H.; Chen, J. J. Mini. Rev. Med. 
Chem. 2013, 13, 749–776. 
[18] Trost, J. J.; Brown, B. S.; McEachern, E. J.; Kuhn, O. Chem. Eur. 
J. 2003, 9, 4442–4451. 
[19] Verendel, J. J.; Li, J. Q.; Quan, X.; Peters, B.; Zhou, T. G.;  
Gautun, O. R.; Govender, T.; Andersson, P. G. Chem. Eur. J. 
2012, 18, 6507–6513. 
[20] Takayama, H.; Ishikawa, H.; Kitajima, M.; Aimi, N.; Aji, B. M. 
Chem. Pharm. Bull. 2004, 52, 359–361. 
[21] Nie, R. L.; He, R. Y. Acta Bot. Yunnan. 1984, 6, 325–328. 
[22] Suhr, J. H.; Arends, P.; Jensen, B. Phytochemistry 1978, 17, 
135–138. 
[23] Vander, N. J.; Vander, S. W. G.; Labadie, R. P. Planta Med. 
1982, 45, 161–162. 
[24] Cheng, M. J.; Tsai, I. L.; Chen, I. S. J. Chin. Chem. Soc. 2001, 48, 
235–239. 
 
